Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:508-510

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinderliter, A. L.
Right arrow Articles by Runge, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinderliter, A. L.
Right arrow Articles by Runge, M. S.
Related Collections
Right arrowRelated Article

(Circulation. 2001;104:508.)
© 2001 American Heart Association, Inc.


Editorial

Who’s on First?

Does Hypertension in Type I Diabetics Result From Nephropathy or Metabolic Alterations?

Alan L. Hinderliter, MD; Marschall S. Runge, MD, PhD

From the Department of Medicine (M.S.R.) and the Division of Cardiology (A.L.H.), University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC.

Correspondence to Alan L. Hinderliter, MD, Division of Cardiology, University of North Carolina, CB #7075, 338 Burnett-Womack, Chapel Hill, NC, 27599-7075 (E-mail hinderli@med.unc.edu) or to Marschall S. Runge, MD, PhD, Chair, Department of Medicine, University of North Carolina, CB #7005, Room 3033, Chapel Hill, NC 27599-7005 (E-mail mrunge@med.unc.edu).


Key Words: Editorials • hypertension • diabetes mellitus

It has long been assumed that end-organ damage by the metabolic abnormalities associated with type I diabetes mellitus occurs before clinically evident adverse outcomes. However, the study reported by Elliott et al1 in the present issue of Circulation suggests that it is time to reconsider this hypothesis.

See p 563

Patients with diabetes mellitus are at a high risk of cardiovascular events. Observational studies suggest that cardiovascular morbidity is {approx}2 times higher in diabetics than in the general population, and that cardiovascular disease accounts for {approx}70% of all deaths in people with diabetes mellitus.2,3 The risk of vascular events is further heightened by coexistent hypertension. As in the general population, there is a strong, graded relationship between hypertension and coronary heart disease and stroke in diabetic patients, independent of other traditional risk factors.4 In diabetics, as in nondiabetics, most studies focus on the treatment of hypertension as a surrogate end point for cardiac risk reduction.

Treatment of Hypertension in Patients With Diabetes Mellitus

Acknowledgment of the excessive risk of cardiovascular events in patients with diabetes and hypertension has led to numerous studies on the potential benefits of optimizing antihypertensive therapy in this population. The results of several recent clinical trials demonstrate that rigorous control of arterial pressure in patients with diabetes markedly reduces morbidity and mortality from cardiovascular disease. In the Hypertension Optimal Treatment (HOT) trial, hypertensive patients were randomized to 1 of 3 diastolic blood pressure targets: <=90 mm Hg, <=85 mm Hg, or <=80 mm Hg. Initial therapy was with felodipine, and an ACE inhibitor or . . . [Full Text of this Article]


Related Article:

Improvement in Hypertension in Patients With Diabetes Mellitus After Kidney/Pancreas Transplantation
Michael D. Elliott, Ajoy Kapoor, Michele A. Parker, Dixon B. Kaufman, Robert O. Bonow, and Mihai Gheorghiade
Circulation 2001 104: 563-569. [Abstract] [Full Text]